NewLink Genetics Corporation (NLNK) Traders Should Start Listening to Analysts

Henrietta Strickland
June 9, 2017

Shares of NewLink Genetics Corporation (NASDAQ:NLNK) are showing high volatlity in today's session as the stock has moved 7.53%, clocking in at $6.71 after a recent bid. 2,167,853 shares of the stock traded hands. Jefferies Group LLC reiterated a "hold" rating and issued a $18.00 price objective on shares of NewLink Genetics Corp in a research report on Monday, May 15th. NewLink Genetics Corp has a 12-month low of $6.03 and a 12-month high of $25.17.

Over the last 5 years, NewLink Genetics Corporation has averaged a 0.30% YoY EPS growth rate and a 80.40% revenue growth rate. EPS breaks down the profitability of the company on a single share basis. Analysts have placed a $26.8 price target on NewLink Genetics Corporation, suggesting a 329.49% gain from recent close. Sun Trust Rbsn Humphrey had a markedly different take on 11/05/2016, proposing that NewLink Genetics Corporation is now considered Neutral versus prior Buy rating.

Market Capitalization can be thought of as the overall price to buy the company. NewLink Genetics Corp now has an average rating of "Hold" and an average price target of $23.80. Finally, Teachers Advisors LLC boosted its stake in shares of NewLink Genetics Corp by 2.8% in the fourth quarter. Several institutional investors have recently modified their holdings of the company. Tyers Asset Management LLC purchased a new stake in shares of NewLink Genetics Corp during the fourth quarter valued at $114,000.

This stock (NLNK) is ahead of its 52-week low with -35.4%.

NewLink Genetics Corporation has a consensus outperform rating from 5 Wall Street analysts, and the number of shares now sold short amount to at least 17.92% of shares outstanding. Over the past 2 quarters, the stock is down -44.63%, compared with a fall of almost -70.30% for 3 months and about -62.68% for the past 30 days. The company is expected to report EPS as high as $-0.49 and as low as $-1.13 per share. NewLink Genetics Corp had a negative return on equity of 68.81% and a negative net margin of 757.44%. If you are accessing this article on another domain, it was stolen and reposted in violation of U.S. & worldwide trademark and copyright laws. The original version of this report can be read at https://sportsperspectives.com/2017/06/07/glen-harbor-capital-management-llc-has-569000-stake-in-newlink-genetics-corp-nlnk-updated-updated-updated.html. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $32.00 price target (up previously from $20.00) on shares of NewLink Genetics Corp in a research note on Saturday, April 22nd. Wells Fargo & Company MN now owns 162,926 shares of the biotechnology company's stock valued at $3,926,000 after buying an additional 4,701 shares during the last quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company's stock valued at $321,000 after buying an additional 880 shares during the last quarter.

GDC-0919 (navoximod), an immuno-oncology product candidate.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER